Rise Advisors’s Genmab GMAB Stock Holding History

Rise Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-577	Closed	-$12K	–	1524
2024 Q4	$12K	Hold	577	–	–	0.01%	933
2024 Q3	$14.1K	Hold	577	–	–	0.01%	902
2024 Q2	$14.5K	Hold	577	–	–	0.01%	847
2024 Q1	$17.3K	Buy	+577	New	+$16.9K	0.01%	753

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rise Advisors's GMAB Position: Q1 2025 in Review

Rise Advisors sold out of Genmab (GMAB) in Q1 2025, closing a stake of 577 shares — an estimated $12K sold.

Rise Advisors first reported a position in GMAB in Q1 2024 and held it in 4 quarters. The position peaked at $17.3K in Q1 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

Rise Advisors reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
Rise Advisors sold 577 Genmab shares in Q1 2025, an estimated $12K.
Rise Advisors first reported a position in Genmab in Q1 2024 and held it in 4 quarters.
Rise Advisors's Genmab position peaked at $17.3K in Q1 2024.
219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Rise Advisors's 13F filing for Q1 2025, filed 15 May 2025.